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Abstract: Gemcitabine is a chemotherapeutic agent used for the treatment of a number of malignancies. Although its major   dose-limiting 
side effect is myelosuppression, many pulmonary toxicities have been described with its use. Severe pulmonary toxicity is rare, but 
symptoms tend to be rapid in onset and potentially deadly. The average time from initiation of chemotherapy to onset of symptoms is 
less than two months. The most effective therapy is steroid administration, the efficacy of which has been variable. In this report, we 
describe a unique case of gemcitabine pulmonary toxicity in a patient who did not experience symptoms of pulmonary dysfunction until 
after 1 year of treatment. Her symptoms did not improve rapidly with steroids, nor did she rapidly decompensate as has been frequently 
described. To our knowledge, this is one of the first reported descriptions of late-onset gemcitabine lung toxicity.
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Introduction
Gemcitabine lung toxicity tends to be quick in onset 
and  rapidly  fatal  with  mortality  rates  reported  at 
upwards of 20%. The average time course from initia-
tion of gemcitabine to onset of symptoms is less than 
two months. Symptoms progress quickly to respira-
tory  failure  unless  steroids  are  initiated  early,  and 
even then response rates are variable. In this report, 
we  describe  an  unusual  presentation  of  late-onset 
gemcitabine-induced lung toxicity in a breast cancer 
patient, where toxicity did not occur until more than a 
year after the initiation of gemcitabine therapy.
case presentation
A 54 year-old female with stage IV invasive   ductal 
carcinoma was found to have progressive   dyspnea 
on  exertion  over  a  three-month  period.  She  had 
no  significant  cardiac  history.  She  was  a  life-long 
  non-smoker  and  had  no  environmental  or  occupa-
tional exposures known to cause lung toxicity. She 
did not have radiation therapy to the chest. She was 
known to have metastatic disease to the lung with a 
known 1.7 cm × 1.3 cm left lower lobe lesion and 
a small loculated left pleural effusion at the time of 
symptom onset, which had been stable for a two year 
period (Fig. 1).
Her  initial  cancer  diagnosis  was  20  years  prior 
when  she  was  found  to  have  a  1.5  cm  mass  with 
  extensive carcinoma in situ present. She underwent 
total    mastectomy  with  ER/PR  positive,  HER-2/neu 
negative  tumor  immunohistochemistry  (T1M0N0).   
She sustained 5 years of tamoxifen therapy, at which 
time  she  was  found  to  have  widespread  metastatic 
disease on computed tomography (CT) scan, which 
included a left upper lobe pleural mass, a left malignant 
pleural effusion, skeletal lesions, and liver lesions.
Over the course of the next 6 years, she under-
went various chemotherapy regimens including doc-
etaxel (9 cycles), vinorelbine, liposomal doxorubicin 
(12 cycles), bevacizumab, and ixabepilone (2 cycles). 
Her course was complicated by multiple pathologic 
fractures requiring whole beam radiation therapy as 
well as Cyber Knife. She underwent a VATS of the 
left lung in 2007 with talc pleurodesis for recurrent 
pleural effusion.
In November of 2008, she was started on single 
agent  gemcitabine.  She  underwent  14  cycles  over 
the course of 12 months (750 mg/m2 days 1, 8 every 
21 days). In September of 2009, she began to expe-
rience an insidious onset of increasing shortness of 
breath with exertion. This progressed slowly over the 
next few months as manifested by decreased exercise 
tolerance. By December of 2009, she was dyspnic at 
rest. During this time, she remained afebrile without 
chest pain, wheezing, or cough. Her exam was only 
pertinent for decreased breath sounds at the left base, 
which had been stable over the two years prior.
On the work up for her progressive dyspnea, CXR 
was negative for infiltrates. CT of the   thorax was neg-
ative for pulmonary embolism but did reveal ground 
glass opacities bilaterally with a new right effusion as 
well as septal wall thickening suspicious for edema 
(Fig.  2).  Echocardiogram  revealed  normal  systolic 
function with an EF of 55%–60%. The patient was 
then evaluated by pulmonology and pulmonary func-
tion tests were performed which demonstrated mod-
erate  to  severe  restriction.  Her  diffusion  capacity 
could not be performed. A 6 min walk test showed 
desaturation within 2 minutes into the low 80% satu-
ration. She was titrated to 3 L of oxygen with exertion.   
A presumptive diagnosis of gemcitabine-induced pul-
monary toxicity was made.
Her  gemcitabine  was  stopped  secondary  to  the 
concern  for  gemcitabine-related  lung  toxicity.  She 
was given a trial of corticosteroids which yielded no 
significant improvement in her pulmonary symptoms.
Repeat CT after steroids showed no change in lung 
findings. She then underwent lung biopsy to evaluate 
Figure 1. CT chest after 10 months of treatment with gemcitabine with 
findings significant for 1.7 cm × 1.3 cm left lower lobe lesion (not pictured 
in this cut) and loculated left pleural effusion.A case of late-onset gemcitabine lung toxicity 
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for other potential diagnoses, specifically   lymphangitic 
carcinomatosis.  The  biopsy    demonstrated  poorly 
differentiated adenocarcinoma with angiolymphatic 
and visceral pleural invasion. However, also present 
were background features of a patchy mononuclear 
infiltrate associated with poorly formed granulomas 
and focally associated pulmonary parenchymal scar-
ring  consistent  with  hypersensitivity  pneumonitis 
(Fig. 4).
Discussion
Gemcitabine is a nucleoside analog used for the treat-
ment of a number of solid tumors including non-small 
cell lung, pancreatic, breast, and ovarian cancer. The 
mechanism of action for anti-tumor activity resides 
in its inhibition of the enzyme, thymidylate synthase. 
The inhibition of this enzyme leads to the inhibition 
of DNA synthesis and ultimately cell death.1
Gemcitabine is generally a well-tolerated chemo-
therapeutic agent, however, wide spectrums of lung 
toxicities have been reported with its use. Dyspnea has 
been reported in up to 25% of patients, regardless of 
severity, at some point during therapy. This was ana-
lyzed in a review of clinical trials with 2,704 patients 
receiving gemcitabine as a single agent. Pulmonary 
side  effects  were  evaluated  using  WHO  recom-
mended toxicity grading: 7.4% reported mild symp-
toms (Grade 1), 7.6% reported dyspnea on   exertion 
(Grade 2), 3.1% reported dyspnea at rest (Grade 3), 
and 0.8% required complete bed rest (Grade 4).2
Although dyspnea is commonly reported during 
gemcitabine treatment, it tends to be transient, rarely 
severe, and often disease related.3 In a recent   analysis 
by Roychowdhury et al, 4,448 patients treated with 
gemcitabine  were  analyzed  on  the  incidence  of 
severe dyspnea and other severe pulmonary   toxicity. 
Only 0.45% and 0.27%, respectively, reported these 
  toxicities  in  clinical  trials  and  0.02%  and  0.06% 
Figure  2.  CT  chest  after  12  months  of  treatment  with  gemcitabine 
revealing ground glass opacities, right pleural effusion, and septal wall 
thickening.
Figure 4. pathology revealing a chronic bronchiolitis with a mononuclear 
alveolar septal infiltrate associated with poorly formed granulomas at the 
upper left (H&e, ×200).
Figure 3. CT chest 5 months after the discontinuation of gemcitabine 
revealing resolution of chemotherapy induced changes, prior loculated 
left pleural effusion noted.Sherrod et al
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reported these toxicities in spontaneous case reports.4 
A second systematic review of 29 clinical trials and 
21 spontaneous case reports by Barlesi et al found 
the  incidence  of  severe  pulmonary  toxicity  to  be 
0%–5%.5
Severe gemcitabine pulmonary toxicity tends to be 
quick in onset and rapidly fatal. The mortality rate 
was reported to be 20% in a recent review by Bar-
lesi, making early   detection of symptoms important.5 
The clinical   presentation includes dyspnea, fatigue, 
fever, and cough.   Peripheral edema, cyanosis, tac-
hypnea, tachycardia, and chest tightness have also 
been reported. Radiologic imaging has been reported 
to frequently show reticulo-nodular interstitial infil-
trates on chest x-ray (CXR), and ground glass opaci-
ties, thick septal lines, reticular opacities, and pleural 
effusions on CT scan. Pulmonary function tests often 
show a restrictive pattern with a decrease in DlCO. 
Histologically, lung biopsies show features such as 
type 2 pneumoncyte hyperplasia, hyaline membrane 
formation, areas of fibrous thickening of the alveolar 
wall and patchy alveolar hemorrhage.6
Gemcitabine-induced lung toxicity is a diagnosis of 
exclusion, and therefore can be difficult to   diagnose. 
Other  causes  of  respiratory  insufficiency  must  be 
excluded including pneumonia, pulmonary embolism, 
congestive heart failure, exacerbation of chronic lung 
conditions and lymphangitic carcinomatosis.
The average time to onset of symptoms is reported 
to be within two months of the initiation of therapy. 
This was reviewed in 55 clinical trials and 92 spon-
taneous reports in patients with gemcitabine-induced 
lung toxicity. In this report by Belknap and colleagues, 
severe toxicity occurred after a median of 48 days.7 
Maniwa and colleagues supported this conclusion as 
they reported an average of 44.4 days from initiation 
of therapy to onset of symptoms.8
Treatment includes supportive therapy with neb-
ulizers  and  supplemental  oxygen.  Discontinuation 
of gemcitabine is essential as re-exposure can lead 
to repeated toxicity.9 Loop diuretics have been used 
for  non-cardiogenic  pulmonary  edema  with  some 
resolution of symptoms reported.10 The most effective 
treatment  thus  far  has  been  steroid  administration. 
Resolution of symptoms with this treatment modal-
ity is variable but can be dramatic. A rapid response 
with complete resolution of symptoms has frequently 
been described. Evidence of pulmonary toxicity on 
imaging  has  also  been  reported  to  resolve  in  this 
subgroup.11–13 In those who did not respond initially 
to steroids, however, rapid respiratory decompensa-
tion has been reported, with death often occurring 
within days to weeks.8,10
Risk  factors  for  gemcitabine-lung  toxicity  are 
debated in the literature. It has been reported that there 
is a potential increased risk in patients with   previous 
pulmonary disease and/or who have   had radiation. 
This has yet to be supported with clinical data. The 
toxicity  does  not  appear  to  result  from  cumula-
tive exposure as patients have been reported to suf-
fer from respiratory distress following one dose of 
gemcitabine.14
It is unclear if toxicities are potentiated with com-
bination chemotherapy as studies thus far have been 
inconclusive.  In  one  report  by  Belknap  et  al,  the 
authors reviewed 178 cases of gemcitabine-induced 
pulmonary injury. They found co-administered ther-
apy rates of toxicity to be 10% to 43%.7 The high-
est rates were reported to occur in Hodgkin’s patients 
being  treated  with  concomitant  bleomycin  therapy 
(22%–42%).16–18  Other  chemotherapy  combinations 
found to have higher incidence of pulmonary toxicity 
included gemcitabine plus vinorelbine, paclitaxel, or 
docetaxel, each of which is known to induce cytokine 
release, leading to increased inflammation and cumu-
lative pulmonary toxicity.7
The  theory  of  cumulative  pulmonary  toxicity 
was supported by Tamiya and colleagues in a recent 
study where 8 of 418 (2.15%) patients on gemcit-
abine alone as opposed to 2 of 15 (11.76%) patients 
on combination therapy developed severe pulmonary 
toxicity. This again suggesting that pulmonary tox-
icity incidence is higher with combination therapy 
(S1  or  erlotinib)  rather  than  gemcitabine  alone.19 
The findings in this study were questioned, however, 
in another review of patients in a FDA freedom of 
information (FDA-FOI) database. In this report, the 
authors, Czarnecki and Voss, found no substantial 
difference in pulmonary toxicity with combination 
therapy of gemcitabine and taxanes as compared to 
gemcitabine alone.15
With regard to our patient, her presentation was 
not  consistent  with  the  clinical  picture  commonly 
seen with gemcitabine lung toxicity. As previously A case of late-onset gemcitabine lung toxicity 
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mentioned, the median onset of symptoms is 48 days. 
This  patient  underwent  12  months  of  therapy  and 
14  cycles  before  a  chronic  progressive  dyspnea 
provoked further evaluation. She was then found to 
have ground glass opacities, septal thickening, and 
a new right-sided pleural effusion on CT as well as 
evidence  of  hypersensitivity  pneumonitis  on  lung 
biopsy. Her symptom onset was slowly progressive, 
in contrast to the severe pulmonary symptoms that 
have been more commonly reported. Upon discon-
tinuation of gemcitabine, the patient was placed on 
3 L of oxygen and was treated with a slow steroid 
taper. She was weaned off oxygen 5 months after 
the  discontinuation  of  gemcitabine  upon  complet-
ing a course of pulmonary rehabilitation. A CT chest 
at that time showed resolution of the ground glass 
opacities, septal thickening, and right pleural effu-
sion. The only remaining lung findings included her 
chronic left pleural thickening with a slight increase 
in size of the left lower lobe lesion now measuring 
2.7 cm × 4.2 cm (Fig. 3).
In most reported cases, patients have experienced 
either  significant  symptomatic  improvement  after 
gemcitabine discontinuation and steroid administra-
tion, or they have progressed rapidly toward respi-
ratory failure. This contrasts the slow improvement 
after discontinuation seen in our patient.
Regarding our patient’s risk factors, she did have 
pulmonary  metastases  with  a  chronic  left  pleural 
effusion requiring VATS, but this had been stable 
for a two-year period prior to symptom onset. She 
had undergone radiation therapy, but this was Cyber 
Knife to vertebral compression fractures, not to the 
lung. She did, however, undergo multiple therapies 
(docetaxel  and  vinorelbine)  which  are  known  to 
cause cytokine release as well as inflammation, pos-
sibly causing a susceptibility for her later pulmonary 
injury.
This is one of the first reported cases of gemcit-
abine pulmonary toxicity occurring after a prolonged 
course  of  gemcitabine  use.  Whereas  many  cases 
occur acutely over days to weeks, this patient’s dys-
pnea progressed slowly over months. Discontinua-
tion of gemcitabine and steroid administration seems 
to have stopped the progression of lung injury, but 
did not offer rapid resolution of symptoms as seen 
in other cases. The presence of pulmonary metastasis 
may have complicated pathologic diagnosis as well 
as treatment. Clinicians must recognize this uncom-
mon presentation of gemcitabine pulmonary toxicity 
as  progression  of  symptoms  may  occur  with  less 
recognizable lung toxicity than published in previous 
reports.
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